A Phase II Clinical Trial to Evaluate the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector)
Condition: COVID-19 Interventions: Biological: Recombinant novel coronavirus vaccine (Adenovirus type 5 vector); Other: Placebo Sponsors: Insitute of Biotechnology, Academy of Military Medical Sciences, PLA of China; CanSino Biologics Inc.; Jiangsu Province Centers for Disease Control and Prevention; Hubei Provincial Center for Disease Control and Prevention Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Academies | Adenoviruses | Biotechnology | Centers for Disease Control and Prevention (CDC) | China Health | Clinical Trials | Coronavirus | COVID-19 | Research | Vaccines